CellResearch Corporation (CRC), a Singapore biotech company, specialising in stem cell technologies derived from umbilical cord lining announces new Scientific Advisory Board (SAB) member: Dr David Armstrong
- Dr David Armstrong, one of the pre-eminent global experts on Diabetic Foot Ulcers joins CRC SAB to facilitate and advise on the development of CorLiCyteTM
- CorLiCyteTM is an umbilical cord lining stem cell therapy, for patients suffering with a Diabetic Foot Ulcer (DFU)
- DFU is a global health emergency that will affect close to 20% of the diabetic population in their lifetime1
- 5-year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer2
Singapore July 19, 2022: Dr David Armstrong joins CellResearch Corporation’s Therapeutics Scientific Advisory Board to provide strategic guidance and advance the company’s innovative scientific platform with a particular focus on the healing of chronic Diabetic Foot Ulcers.
Dr Armstrong is one of the pre-eminent clinicians working in the field of diabetic foot care. He has produced more than 575 peer-reviewed research papers in medical journals as well as authored and contributed to over 100 books. He is also the co-editor of the American Diabetes Association’s (ADA) Clinical Care of the Diabetic Foot, now in its third edition.
He is the founder and organiser of the largest annual international symposium on the diabetic foot in the world. Dr Armstrong is also the Founding President of the American Limb Preservation Society (ALPS), an interdisciplinary medical and surgical society dedicated to eliminating preventable amputation in the USA and worldwide.
“Dr Armstrong is a world leader in the field of Diabetic Foot Ulcers and we are proud and honoured to have him on our Scientific Advisory Board. His experience will be invaluable as we move into Phase 2 planning and beyond.” said Gavin Tan, CEO of CellResearch.
Dr Armstrong added, “Cellular therapy is a promising approach for the treatment of diabetic foot complications that has a growing scientific basis of evidence. I am excited to be supporting the development of this technology, which has the potential to expand the range of treatment options available to patients to tackle the growing, silent, sinister, health emergency of diabetic foot complications.”
Dr Armstrong was the first podiatric surgeon to become a member of the Society of Vascular Surgery and the first US podiatric surgeon named fellow of the Royal College of Surgeons, Glasgow. He was the youngest ever recipient of the ADA’s Roger Pecoraro Award in 2010. This is the highest award given in the field of diabetic foot ulcer research.
This news comes at an opportune moment given the imminent completion of CRC’s Phase 1 USFDA trial to close chronic DFUs at the University of Colorado Anschutz Medical Campus under the identifier NCT04104451.
1 Yazdanpanah L, et al. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018;2018:7631659. Published 2018 Mar 15. doi:10.1155/2018/7631659
2 Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020 Mar 24;13(1):16. doi: 10.1186/s13047-020-00383-2. PMID: 32209136; PMCID: PMC7092527.
About CellResearch Corporation (CRC)
CellResearch Corporation was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialise this technology in most major markets globally. While the closure of diabetic foot ulcers is the company's first allogeneic therapy to make it to the end of Phase 1 USFDA clinical trials, CellResearchCorp has a broad therapeutic pipeline at the pre-clinical stage. Further therapies include inflammatory diseases, Parkinson's Disease, Age-related Macular Degeneration and Critical limb Ischemia.
CALECIM® Cosmeceuticals is a wholly owned subsidiary of CellResearchCorp and produces an innovative range of skincare products using cord lining stem cell media to power its products. It is used post-procedure in clinic and as part of an at-home anti-aging skincare regime. It is distributed globally through over 600 aesthetic physicians and online via their own website. It has a key distribution partnership with Menarini Group across South East Asia.
CRC partner, Cordlife offers parents the opportunity to bank their child's umbilical cord tissue alongside their cord blood. Cordlife has what is believed to be the largest licensed bank of umbilical cord tissue globally. As cell therapies move into the clinic, Cordlife will have the ability to expand stem cells from a banked umbilical cord for autologous and donor-related uses.
www.cellresearchcorp.com
https://calecimprofessional.com
Business Development and Investor Relations:
Xavier Simpson T:+65 8815 6139 E: xaviersimpson@cellresearchcorp.com